Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Home | Back to Search Results

Product Details for NDA 022083

Expand all

EXELON (RIVASTIGMINE)
4.6MG/24HR
Marketing Status: Prescription

Active Ingredient: RIVASTIGMINE
Proprietary Name: EXELON
Dosage Form; Route of Administration: FILM, EXTENDED RELEASE; TRANSDERMAL
Strength: 4.6MG/24HR
Reference Listed Drug: Yes
Reference Standard: No
TE Code: AB
Application Number: N022083
Product Number: 001
Approval Date: Jul 6, 2007
Applicant Holder Full Name: SANDOZ INC
Marketing Status:  Prescription
Patent and Exclusivity Information

EXELON (RIVASTIGMINE)
9.5MG/24HR
Marketing Status: Prescription

Active Ingredient: RIVASTIGMINE
Proprietary Name: EXELON
Dosage Form; Route of Administration: FILM, EXTENDED RELEASE; TRANSDERMAL
Strength: 9.5MG/24HR
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code: AB
Application Number: N022083
Product Number: 002
Approval Date: Jul 6, 2007
Applicant Holder Full Name: SANDOZ INC
Marketing Status:  Prescription
Patent and Exclusivity Information

EXELON (RIVASTIGMINE)
13.3MG/24HR
Marketing Status: Prescription

Active Ingredient: RIVASTIGMINE
Proprietary Name: EXELON
Dosage Form; Route of Administration: FILM, EXTENDED RELEASE; TRANSDERMAL
Strength: 13.3MG/24HR
Reference Listed Drug: Yes
Reference Standard: No
TE Code: AB
Application Number: N022083
Product Number: 005
Approval Date: Aug 31, 2012
Applicant Holder Full Name: SANDOZ INC
Marketing Status:  Prescription
Patent and Exclusivity Information